Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III equivalence trial of IBI3027 vs Dupilumab in adults with moderate-to-severe atopic dermatitis
CTR20263047Phase 3Active
- Sponsor
- InnoCare Pharma
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of IBI3027 in atopic dermatitis (AD), sponsored by InnoCare Pharma. Started Aug 2026; status: active.
02
Drugs
IBI3027
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20263047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263047.